Inactivation resistant factor VIII
View Patent ↗The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences of the present invention also encode amino acid sequences corresponding to known human FVIII sequences, wherein the APC cleavage sites, Arg336 and Ile562, are mutated. The nucleic acid sequences of the present invention further encode amino acid sequences corresponding to known human FVIII sequences, wherein the B-domain is deleted, the von Willebrand factor binding site is deleted, a thrombin cleavage site is mutated and an amino acid sequence spacer is inserted between the A2- and A3-domains. Methods of producing the FVIII proteins of the invention, nucleotide sequences encoding such proteins, pharmaceutical compositions containing the nucleotide sequences or proteins, as well as methods of treating patients suffering from hemophilia, are also provided.
1. A procoagulant-active FVIII protein comprising a human FVIII polypeptide that is modified, wherein the modification comprises a substitution of the Arg residue at position 336 with Ile, a substitution of the Arg residue at position 562 with Lys, and a substitution of Phe at position 309 with Ser, wherein said protein is APC resistant.
2. A pharmaceutical composition comprising an effective amount of the protein of claim 1 in admixture with a parenterally acceptable vehicle or excipient.
3. The procoagulant-active FVIII protein of claim 1 , further comprising a modification selected from the group consisting of a substitution of Leu at position 308 with Glu and a substitution of Gln at position 305 with Lys.
4. A pharmaceutical composition comprising an effective amount of the protein of claim 3 in admixture with a parenterally acceptable vehicle or excipient.